School of Mechanical Engineering, Purdue University, 585 Purdue Mall, West Lafayette, IN 47906, USA.
Lab Chip. 2011 Jul 7;11(13):2212-21. doi: 10.1039/c1lc20111e. Epub 2011 May 20.
For tissue engineering and regenerative medicine, cryopreservation, a technique for preserving biomaterials in the frozen state with cryoprotective agents (CPAs), is critically important for preserving engineered tissues (ETs) as well as cells necessary to create ETs. As more diverse ETs are produced using various cell types, CPAs and corresponding freeze/thaw (F/T) protocols need to be developed cell/tissue-type specifically. This is because CPAs and F/T protocols that have been successful for one cell/tissue type have proven to be difficult to adapt to other cell/tissue types. The most critical barrier to address this challenge is the inability to screen and identify CPA or CPA mixtures efficiently. In this paper, we developed an "electro-wetting-on-dielectic" (EWOD) based digital microfluidic platform to characterize and screen CPA mixtures cell-type specifically. The feasibility of the EWOD platform was demonstrated by characterizing and optimizing a mixture of dimethlysulfoxide (DMSO) and PBS for human breast cancer cell line as model CPA mixture and cell line. The developed platform multiplexed droplets of DMSO and PBS to create an array of DMSO-PBS mixtures, and mapped the phase change diagram of the mixture. After loading cell suspensions on the platform, the mixture was further screened on-chip for toxicity and cryoprotection. The results were discussed to illustrate the capabilities and limitations of the EWOD platform for cell and tissue-type specific optimization of CPA mixtures and F/T protocols.
对于组织工程和再生医学,冷冻保存是一种将生物材料在冷冻状态下用冷冻保护剂(CPAs)保存的技术,对于保存工程组织(ETs)以及创建 ETs 所需的细胞至关重要。随着使用各种细胞类型生产更多样化的 ETs,需要专门针对细胞/组织类型开发 CPAs 和相应的冷冻/解冻(F/T)方案。这是因为已经成功用于一种细胞/组织类型的 CPAs 和 F/T 方案已被证明难以适应其他细胞/组织类型。解决这一挑战的最关键障碍是无法有效地筛选和识别 CPA 或 CPA 混合物。在本文中,我们开发了一种基于“电润湿在电介质上”(EWOD)的数字微流控平台,以专门针对细胞类型对 CPA 混合物进行表征和筛选。通过对二甲亚砜(DMSO)和 PBS 的混合物进行表征和优化,以人乳腺癌细胞系作为模型 CPA 混合物和细胞系,证明了 EWOD 平台的可行性。该平台将 DMSO 和 PBS 的液滴多路复用,以创建 DMSO-PBS 混合物的阵列,并绘制混合物的相图。在平台上加载细胞悬浮液后,进一步在芯片上对混合物进行毒性和冷冻保护作用筛选。讨论结果说明了 EWOD 平台用于针对细胞和组织类型专门优化 CPA 混合物和 F/T 方案的能力和局限性。